가축용 백신 시장 보고서 : 동향, 예측 및 경쟁 분석(-2035년)

Livestock Animal Vaccine Market

The future of the global livestock animal vaccine market looks promising with opportunities in the live attenuated vaccine and inactivated vaccine markets. The global livestock animal vaccine market is expected to reach an estimated $9.1 billion by 2035 from $6.6 billion in 2027 with a CAGR of 3.9% from 2027 to 2035. The major drivers for this market are the increasing demand for disease free livestock, the rising focus on preventive animal healthcare, and the growing adoption of advanced veterinary vaccines.

• Lucintel forecasts that, within the application category, pig is expected to witness the highest growth over the forecast period due to more pig farming and greater potential for the spread of transboundary animal diseases.
• Within the type category, inactivated vaccine is expected to witness higher growth over the forecast period due to traditional inactivated vaccines are safer.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to rise of animal husbandry and increased investment in animal health and welfare.

Emerging Trends in Livestock Animal Vaccine Market

The focus of the livestock vaccine market is expected to be on prevention, surveillance and control of livestock productivity from 2025 to 2027. Lucintel anticipates this trend based upon the increase in livestock unit densities, increasing demands for safe animal food products and the growing investment in veterinary vaccines. The market prefers vaccines that help accomplish the goal of reducing the dependence on antibiotics while helping to implement integrated prevention and control programs of livestock diseases.

• Preventive Health Management: To control livestock diseases, vaccination is preferred over treatment; prevention of disease is an effective approach to control antimicrobial resistance and other zoonotic infections. Due to the increasing threat of transboundary animal diseases, many countries have expansive vaccination programs against avian and swine diseases. From an economic perspective, it is prudent to implement preventive measures to stop the spread of diseases as the cost of preventing the spread of diseases is less than the economic loss caused by diseases and trade restrictions.
• Vaccine Formulations: There is focus in improving the stability, Cold Chain and Field readiness of vaccines. While many remote areas are difficult to access and vaccinate, improving stability of vaccines will increase the scope of prevention of livestock diseases.
• Vaccine Efficacy Surveillance: Improving the diagnostic tests for livestock diseases will further help in determining the scope of vaccination against particular diseases. In 2025, several veterinary diagnostic laboratories began offering next generation genetic sequencing of animal pathogens to veterinarians. This will help veterinarians to better understand the scope of prevention of trans-boundary animal diseases.
• Competitor Combination and Platform Vaccines: Expectations for next generation combination vaccines are increasing. Manufacturers are also investing in vector-based and recombinant technology as well as developing multivalent vaccines. In the next few years, expect to see vaccines protecting against multiple pathogens. These platforms allow vaccine manufacturers to be more nimble in the face of regional variation.
• A Greater Vaccine and Biologics Production on A Regional Basis: Many high-income countries and major suppliers are also investing to build local biologics capacity to address gaps in supply. Several countries in Africa and Asia are also investing to build regional vaccine production capacities. These investments should increase supply, improve the timeliness of supply to meet local demand, and improve the range of vaccine options to meet local needs.

Growth will be related to the health and wellness of livestock more than the vaccines themselves. Traditionally, the gaps in livestock health and wellness have correlated to gaps in the productivity of the agriculture sector. In the next five years, improvements in the infrastructure to support the movement of vaccines and related supplies should improve the health and productivity of livestock in the developing world

Recent Developments in the Livestock Animal Vaccine Market

The next few years should see more investments in the livestock vaccine market as the surveillance of livestock diseases has increased, and the cattle industry has become more regulatory and competitive. As a result, Lucintel expects the focus of the investments to be on recombinant technologies. In addition, facilities to manufacture vaccines and a reliable cold chain distribution system will be key.

• Manufacturing: Boehringer Ingelheim Vetmedica GmbH (BI) committed €100 million to construct a new livestock vaccine manufacturing plant in France (January 2025).
• Partnership: In February 2025, MSD Animal Health and Hester Biosciences announced a collaboration to jointly market animal vaccines in India.
• Innovation: Zoetis expanded its product offerings for U.S. dairy farmers, including a suite of sensors and diagnostics (2025). This represents the continued shift in the livestock health and vaccination market, to value more products which result in measurable improvements in livestock health and productivity as opposed to products which are simply branded.
• Faster Policy Responses: The European Commission's 2025 approval of a broader range of applications for the avian influenza vaccine indicated that the EU was strengthening its policy response to high-impact outbreaks. The approval also signaled that regulatory bodies are becoming more receptive to the use of avian influenza vaccines. The potential changes to policy and regulation are likely to enable the prevention of avian influenza and shape international trade in poultry and poultry products.
• Localization of Production: The Indian government subsidized and/or controlled the purchase of veterinary biologicals in 2025, thereby promoting local manufacturing. It is expected that local production of veterinary biologicals will be available in the Indian market in the coming years, which is likely to impact import dependency and increase price competition.

Advancements in veterinary medicine are enabling planned prevention of animal diseases. Manufacturers of animal vaccines will compete based on the reliability of vaccine supply, convenience of administration, and evidence that the vaccine impact improves profit margin. Company-specific regulation of animal vaccines will require that companies have a presence in target geographies. Cattle are expected to gain increased focus due to the need to increase crop and livestock productivity and reduce the use of antibiotics. For the next five years, vaccines will be a core component of the animal health portfolio. Companies integrating animal health vaccines, diagnostics and/or monitoring will be the most competitive.

Strategic Growth Opportunities in the Livestock Animal Vaccine Market

Livestock vaccines are in an extended market cycle as surveillance of infectious diseases of livestock has improved. Biosecurity spending has also trended upwards. Past trends have shown that farmers prefer to invest in vaccination to prevent diseases rather than spend on medicines to control or eradicate diseases. Between 2024 and 2026, factors including climate change, and expansion in protein production create an opportunity for livestock vaccines. During this period, Lucintel expects that the market trend would shift to prioritization of regional and advanced supply of veterinary vaccines.

• Disease Vaccines: Transboundary animal diseases like African swine fever (ASF) and influenzas offer market potential for vaccines. As of January 2025, ASF was reported to be over 60 countries as per the World Organization for Animal Health (WOAH).
• Precision Livestock: Continuous and real time monitoring of livestock can facilitate the use of customized and differentiated vaccination services. The European Commission's proposal for a regulation on the use of electronic identification and other technologies for the monitoring of livestock entered into force in June 2025.
• Aquaculture and Other Protein Sources: Increasing livestock and fish production creates additional opportunities and needs for livestock and fish vaccination. As of February 2025, the UN Food and Agriculture Organization (FAO) estimated that the global aquaculture production was approximately 85 million tons.
• Thermostable and Adjuvanted Vaccines: Vaccines tolerant to transport interruptions can reach smallholder and remote farmers. Gavi reported in 2025 that that logistics to maintain vaccine cold chain can account for 80% of the vaccine cost. Long-lasting vaccines can solve the problem of vaccine waste and increase vaccine coverage.
• Regional Manufacturing and Licensing: Rapid response manufacturing contracts and other joint ventures can address the needs of emerging markets. It was reported in 2026 that the livestock population of India was 500 million. Regional manufacturing of vaccines will also allow vendors to gain public and private contracts for the supply of vaccines in the area in the next 3-5 years.

Demand for veterinary vaccines is expected to increase in the coming years. More end-users are requesting vaccines beyond preventive measures. There is an increased interest for vaccines to prevent specific diseases. Lead times for regulatory approvals for emergency vaccines is expected to decrease. Companies that can produce farm-relevant vaccines and combine it with a strong cold chain will have an edge in the market.

Livestock Animal Vaccine Market Drivers and Challenges

Rising threats from pathogens and increased focus on sustainable development in the livestock sector presents a potential market for vaccines. There is an increasing emphasis on improved livestock health, reduction in livestock mortality and the judicious use of antimicrobials. Novel biotechnologies facilitate the development of vaccines for complex pathogens. The focus on Harmonization of Veterinary regulations, together with the reforms and modernization of the transportation and Cold Chain Infrastructure provide opportunities for equal distribution of vaccines. According to Lucintel, the next three to five years are expected to witness continued transitions in the livestock production systems and in the required levels of biosecurity. This is expected to shape the market and industry competition structure.

The factors responsible for driving this market include:

• Increasing Customer Demand: Increased global population, changing dietary preferences and the resultant accelerated growth in meat, egg and dairy production create an imperative for improving the productivity and health of livestock. The FAO projects that by 2050, all components of world agriculture including livestock will need to increase its productivity.
• New Technologies: Recent innovations in vaccine technologies including the use of mRNA and vectors has shortened the time required to develop vaccines and improved the type and level of protection afforded by vaccines. Simultaneously, improvements in genomic sequencing, surveillance, and other monitoring technologies have facilitated the real-time detection and tracking of pathogens. Between 2021 and 2025, rapid improvements in technologies, especially in human health, increased interest in the development and use of similar platforms in the veterinary field. The use of adjuvants improved the formulation of multivalent, thermostable, and single-dose vaccines. Better diagnostic and vaccination technologies and improved veterinary public health emergency responses will be achieved in the next three to five years.
• Regulatory Changes: The growing interest in increasing food and veterinary public health through the free movement of commodities and trade has promoted countries to strengthen their legislative and regulatory frameworks to protect the health of animals under their control and facilitate the free movement of commodities and trade. In the next three to five years, increased harmonization of veterinary public health regulatory standards is expected to positively impact the veterinary biopharmaceutical industry, especially for the control of transboundary animal diseases of poultry, swine and cattle.
• Sustainability: Sustainability in livestock production relies on the optimization of numerous factors, including feed, energy, water and other resources. Unnecessary losses due to disease increase production costs. Preventative measures, including vaccination, play an important role in enhancing sustainability. The World Health Organization (WHO) classifies antimicrobial resistance as a critical human health issue. Consequently, the goal of the agriculture industry is to integrate practices which reduce the reliance on antimicrobials. Integrating vaccination programs in livestock production helps to optimize resource use. Reductions in meat and milk production losses increase farm efficiency and reduce greenhouse gas emissions. Within the next three to five years, primarily due to the increasing concern for the protection of the environment and the welfare of farm animals, preventive vaccination programs are expected to gain greater industry acceptance.
• Manufacturing: The increasing geographical concentration of the biologics industry, coupled with the sophistication of the bioprocessing, formulation and cold chain technologies, continues to favor the vaccine industry. In 2025, the goal of many biologics manufacturers was to build local production capacities in developing countries to improve access to vaccines. The lack of economies of scale in the vaccine manufacturing industry, coupled with the investment needed to implement advanced processes and quality control, prevents reduction in the cost of vaccines. Within the vaccine industry, automation and information technologies facilitate the rapid response required for the production of vaccines against emerging infectious diseases. These advancements are expected to benefit primarily small and medium-size farming operations.

The challenges facing this market include:

• Cold-Chain and Distribution: Many vaccines lose potency during transport and storage due to unstable electricity supply. Further, veterinary services may be unavailable or long distances away. Rural areas of developing nations have the greatest need for improved vaccine supply and distribution. Improved veterinary distribution and storage of vaccines, as well as the development of vaccines that are more temperature stable and easier to transport, will contribute to the rural areas of developing countries where the need is greatest.
• Production and Development: The cost and length of time required for the development and production of veterinary vaccines, as compared to human vaccines, has left a significant number of potential vaccines unexplored and undeveloped. The cost and time required to complete the development and production of multivalent vaccines, as compared to monovalent vaccines, has created a significant cost barrier to completing the development and production of vaccines to control economically important livestock diseases. In the upcoming years, it is expected that costs and time required for development of veterinary biologics would continue to stifle innovation. Limited resources would be directed toward those diseases that primarily affect high-income livestock markets.
• Variability of Disease and Farmer Acceptance of Veterinary Vaccines: Mutation of pathogens, variability of strains of a particular pathogen, inadequate diagnostic tests, and inconsistent compliance of farmers, can limit the efficacy of veterinary vaccines. Cost and the perception of the benefits of vaccination, awareness, and the labor required for their administration, can also affect the acceptance of veterinary vaccination. In 2025, several outbreaks of avian influenza and other transboundary animal diseases, illustrate the rapid changes in the high-health status of the animal populations and the disruption of international trade. It is expected that within the next 3 to 5 years, the veterinary services sector would have established adequate veterinary services and improved surveillance to increase the acceptance of vaccination by farmers.

There is considerable potential for the growth of the animal vaccination market as a consequence of reduction in the prevalence of animal diseases, increase in agricultural production, and improving the sustainability of the farming industry. Improvement in biotechnology, and partnerships between regulatory agencies, would facilitate the increase in supply of animal vaccines. Increasing demand from emerging countries and improved economy of large animal farming would increase the acceptance of animal vaccination. Advances in distribution and collaboration by governments and the veterinary and farming professions would facilitate the use of veterinary vaccines. Of major concern is the availability of affordable veterinary vaccines.

List of Livestock Animal Vaccine Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies livestock animal vaccine market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the livestock animal vaccine market companies profiled in this report include-

• Merck
• Boehringer Ingelheim
• Zoetis
• Ceva
• Elanco

Livestock Animal Vaccine Market by Segment

The study includes a forecast for the global livestock animal vaccine market by type, application, and region.

Livestock Animal Vaccine Market by Type [Value ($B) from 2019 to 2035]:

• Live Attenuated Vaccine
• Inactivated Vaccine
• Others

Livestock Animal Vaccine Market by Application [Value ($B) from 2019 to 2035]:

• Pig
• Cattle
• Poultry
• Others

Livestock Animal Vaccine Market by Region [Value ($B) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Livestock Animal Vaccine Market

Stricter policies on the control of animal diseases have created opportunities for the development of the livestock vaccines industry in different regions of the world. The period 2025-2027 is expected to see increased vaccination efforts against avian influenza, foot-and-mouth disease and African swine fever. Based on Lucintel's research, vaccination policy will continue to be influential.

• United States: The US Department of Agriculture (USDA) announced a series of policies worth about $1 billion in February 2025 to address H5N1. The USDA's policies promoted the enhanced biosecurity of farms and provided financial assistance to farmers to help cover the costs of testing for the presence of zoonotic diseases on farm premises. The USDA also funded on-farm measures to control zoonotic diseases. It is expected that in the next 3-5 years, these policies would promote the development and implementation of cattle, poultry and swine vaccination programs.
• China: China is implementing its 2022-2025 National Plan to control Animal Epidemics. As reported by China's Department of Agriculture, Foot and Mouth Disease (FMD) vaccination was obligatory for all livestock. Other diseases included African Swine Fever and Highly Pathogenic Avian Influenza. The above-mentioned policies facilitate improving the local livestock vaccination industries in China.
• Germany: Foot-and-Mouth: Following the confirmation of FMD cases in Brandenburg in January 2025, Germany implemented movement controls and actively discussed emergency vaccination within the framework of the EU. FMD has not been reported in Germany since 1988. While vaccination banks, laboratory diagnostics and other preventative measures will be enhanced, efforts to improve trace-out and transit controls for livestock will continue.
• India: Free Veterinary Services: The National Animal Disease Control Program continued free veterinary services against FMD and Brucellosis in 2025. New localized poultry outbreaks and continued government commitments to supply the services further strengthened the demand for and supported the production of livestock vaccines in India.
• Japan: Avian Influenza: During the 2024-2025 school year, Japan experienced multiple cases of highly pathogenic avian influenza in poultry and imposed quarantines and bird movement restrictions. Similar events in previous years strengthened Japan's commitment to improving avian influenza vaccine research, development and production.

Features of the Global Livestock Animal Vaccine Market

• Market Size Estimates: livestock animal vaccine market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: livestock animal vaccine market size by type, application, and region in terms of value ($B).
• Regional Analysis: livestock animal vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the livestock animal vaccine market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the livestock animal vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the livestock animal vaccine market by type (live attenuated vaccine, inactivated vaccine, and others), application (pig, cattle, poultry, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Livestock Animal Vaccine Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Live Attenuated Vaccine : Trends and Forecast 2019 to 2035
• 4.4 Inactivated Vaccine : Trends and Forecast 2019 to 2035
• 4.5 Others : Trends and Forecast 2019 to 2035

5. Global Livestock Animal Vaccine Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Pig : Trends and Forecast 2019 to 2035
• 5.4 Cattle : Trends and Forecast 2019 to 2035
• 5.5 Poultry : Trends and Forecast 2019 to 2035
• 5.6 Others : Trends and Forecast 2019 to 2035

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Livestock Animal Vaccine Market by Region

7. North American Livestock Animal Vaccine Market

• 7.1 Overview
• 7.2 North American Livestock Animal Vaccine Market by Type
• 7.3 North American Livestock Animal Vaccine Market by Application
• 7.4 The United States Livestock Animal Vaccine Market
• 7.5 Canadian Livestock Animal Vaccine Market
• 7.6 Mexican Livestock Animal Vaccine Market

8. European Livestock Animal Vaccine Market

• 8.1 Overview
• 8.2 European Livestock Animal Vaccine Market by Type
• 8.3 European Livestock Animal Vaccine Market by Application
• 8.4 German Livestock Animal Vaccine Market
• 8.5 French Livestock Animal Vaccine Market
• 8.6 Italian Livestock Animal Vaccine Market
• 8.7 Spanish Livestock Animal Vaccine Market
• 8.8 The United Kingdom Livestock Animal Vaccine Market

9. APAC Livestock Animal Vaccine Market

• 9.1 Overview
• 9.2 APAC Livestock Animal Vaccine Market by Type
• 9.3 APAC Livestock Animal Vaccine Market by Application
• 9.4 Chinese Livestock Animal Vaccine Market
• 9.5 Indian Livestock Animal Vaccine Market
• 9.6 Japanese Livestock Animal Vaccine Market
• 9.7 South Korean Livestock Animal Vaccine Market
• 9.8 Indonesian Livestock Animal Vaccine Market

10. ROW Livestock Animal Vaccine Market

• 10.1 Overview
• 10.2 ROW Livestock Animal Vaccine Market by Type
• 10.3 ROW Livestock Animal Vaccine Market by Application
• 10.4 Middle Eastern Livestock Animal Vaccine Market
• 10.5 South American Livestock Animal Vaccine Market
• 10.6 African Livestock Animal Vaccine Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunity by Type
  • 12.2.2 Growth Opportunity by Application
• 12.3 Emerging Trends in the Global Livestock Animal Vaccine Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis Overview
• 13.2 Merck
  • Company Overview
  • Livestock Animal Vaccine Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Boehringer Ingelheim
  • Company Overview
  • Livestock Animal Vaccine Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Zoetis
  • Company Overview
  • Livestock Animal Vaccine Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Ceva
  • Company Overview
  • Livestock Animal Vaccine Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Elanco
  • Company Overview
  • Livestock Animal Vaccine Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 CAHIC
  • Company Overview
  • Livestock Animal Vaccine Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Jinyu Bio-Technology
  • Company Overview
  • Livestock Animal Vaccine Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 HVRI
  • Company Overview
  • Livestock Animal Vaccine Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 Ringpu Biology
  • Company Overview
  • Livestock Animal Vaccine Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 Yebio
  • Company Overview
  • Livestock Animal Vaccine Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us